Sai Life Sciences is currently trading at RS. 756.85, rising by 27.65 points or 3.79% from its previous close of RS. 729.20 on the BSE.

The stock opened at RS. 735.00 and touched an intraday high of RS. 766.55 and a low of RS. 720.35. So far, 2,09,91,905 shares have been traded on the counter.

A BSE group 'B' stock with a face value of RS. 1, Sai Life Sciences hit a 52-week high of RS. 808.20 on December 26, 2024, and a 52-week low of RS. 635.30 on April 9, 2025. Over the last week, the stock’s high and low were RS. 772.60 and RS. 716.00, respectively. The company currently holds a market capitalization of RS. 15,535.19 crore.

The company’s shareholding pattern includes 35.17% held by promoters, 25.62% by institutions, and 39.21% by non-institutional investors.

In a major operational update, Sai Life Sciences has commenced commercial production in the second phase of its Unit IV Bidar facility in Karnataka, with an added capacity of 91 kL. This marks the completion of a total 195 kL expansion, as detailed in its prospectus.

With this addition, the total capacity of the Bidar Unit IV now stands at 640 kL. The facility is equipped to produce registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for both clinical trials and commercial manufacturing.

Sai Life Sciences is a fully-integrated, innovator-focused contract research, development, and manufacturing organization serving global pharmaceutical partners.